Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 25.83M P/E - EPS this Y 16.00% Ern Qtrly Grth -
Income -24.57M Forward P/E -1.18 EPS next Y 14.30% 50D Avg Chg -94.00%
Sales - PEG -0.02 EPS past 5Y - 200D Avg Chg -95.00%
Dividend N/A Price/Book 0.31 EPS next 5Y 60.00% 52W High Chg -98.00%
Recommedations 2.00 Quick Ratio 21.74 Shares Outstanding 60.58M 52W Low Chg 12.00%
Insider Own 2.85% ROA -17.45% Shares Float 59.17M Beta 0.91
Inst Own 19.50% ROE -26.31% Shares Shorted/Prior 477.88K/466.55K Price 0.43
Gross Margin - Profit Margin - Avg. Volume 79,645 Target Price 4.50
Oper. Margin - Earnings Date Nov 2 Volume 26,946,654 Change -16.75%
Caladrius Biosciences, Inc. News
09/16/22 Life Sciences Virtual Investor Conference: Presentations Now Available for On-Demand Viewing
09/15/22 Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
09/14/22 Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics
09/12/22 Life Sciences Virtual Investor Conference Agenda Announced for September 15th
09/08/22 Caladrius Biosciences Announces Participation in Upcoming Investor Conferences in September 2022
08/10/22 Caladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic Cancer
08/04/22 Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
08/02/22 Caladrius Biosciences Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney Disease
07/28/22 Caladrius Biosciences to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022, at 4:30 p.m. Eastern Time
07/06/22 Caladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in The Lancet Gastroenterology and Hepatology
06/09/22 Caladrius Biosciences Announces Merger Partner, Cend Therapeutics, has Treated First Patient in Phase 2b Trial of CEND-1 in Collaboration with Australasian Gastro-Intestinal Cancer Trials Group
06/08/22 Caladrius Biosciences to Present at the BIO International Convention 2022
07:00 AM Caladrius Biosciences and Cend Therapeutics Announce Poster Presentation at the 2022 American Society of Clinical Oncology Annual Meeting
05/24/22 Caladrius Biosciences Stops Enrollment In Mid-Stage Heart Disease Study
05/23/22 Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA® in Coronary Microvascular Dysfunction
05/19/22 Caladrius Biosciences Announces IDMC Recommendation to Advance CLBS201 Trial for the Treatment of Diabetic Kidney Disease
05/18/22 Caladrius Biosciences to Present at the H.C. Wainwright Global Investment Conference
05/06/22 Is Caladrius Biosciences (NASDAQ:CLBS) In A Good Position To Deliver On Growth Plans?
05/05/22 Caladrius Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.